Ono Pharmaceutical Co Ltd
TSE:4528

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
TSE:4528
Watchlist
Price: 1 606 JPY -0.12% Market Closed
Market Cap: 754.2B JPY
Have any thoughts about
Ono Pharmaceutical Co Ltd?
Write Note
Ono Pharmaceutical Co Ltd
/
Cash Flow Statement
/
Depreciation & Amortization

Ono Pharmaceutical Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ono Pharmaceutical Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Ono Pharmaceutical Co Ltd
TSE:4528
Depreciation & Amortization
¥18.1B
CAGR 3-Years
3%
CAGR 5-Years
8%
CAGR 10-Years
12%
Takeda Pharmaceutical Co Ltd
TSE:4502
Depreciation & Amortization
¥758.5B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
13%
Daiichi Sankyo Co Ltd
TSE:4568
Depreciation & Amortization
¥64.4B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
6%
Otsuka Holdings Co Ltd
TSE:4578
Depreciation & Amortization
¥107.9B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Depreciation & Amortization
¥31.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Depreciation & Amortization
¥195.9B
CAGR 3-Years
38%
CAGR 5-Years
26%
CAGR 10-Years
12%
No Stocks Found

Ono Pharmaceutical Co Ltd
Glance View

Market Cap
754.4B JPY
Industry
Pharmaceuticals

In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.

Intrinsic Value
2 699.78 JPY
Undervaluation 41%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Ono Pharmaceutical Co Ltd's Depreciation & Amortization?
Depreciation & Amortization
18.1B JPY

Based on the financial report for Sep 30, 2024, Ono Pharmaceutical Co Ltd's Depreciation & Amortization amounts to 18.1B JPY.

What is Ono Pharmaceutical Co Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
12%

Over the last year, the Depreciation & Amortization growth was 1%. The average annual Depreciation & Amortization growth rates for Ono Pharmaceutical Co Ltd have been 3% over the past three years , 8% over the past five years , and 12% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.